Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax Real-World Observational Study on Effectiveness and Treatment Management in Patients With Newly Diagnosed AML Who Are Ineligible for Intensive Chemotherapy in Italy

NCT06058741 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06058741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06058741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax Real-World Observational Study on Effectiveness and Treatment Management in Patients With Newly Diagnosed AML Who Are Ineligible for Intensive Chemotherapy in Italy
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
March 4, 2024
Completion date
July 21, 2026
Enrollment
151 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia